Despite impressive progress in understanding the pathogenesis of cancer over the past decade, in the United States, >600,000 people die of cancer annually and ∼2 million will receive a new cancer diagnosis. Generative AI and biomedical innovation provide exciting new tools to improve these dire statistics. But we must find ways to get smart about using all this information.
Get full access to this article
View all access options for this article.
References
1.
PlacidoD, YuanB, HjaltelinJX, et al.A deep learning algorithm to predict risk of pancreatic cancer from disease trajectories. Nat Med, 2023;29:1113–1122; doi: 10.1038/s41591-023-02332-5
2.
HartGR, YanV, NartowtBJ, et al.Statistical biopsy: An emerging screening approach for early detection of cancers. Front Artif Intell, 2023;5:1059093; doi: 10.3389/frai.2022.1059093
3.
TorkamaniA, WineingerNE, TopolEJ. The personal and clinical utility of polygenic risk scores. Nat Rev Genet, 2018;19:581–590; doi: 10.1038/s41576-018-0018-x
4.
ParkJH, OhY, ChungLI-Y, et al.Systematic review and meta-analysis of the accuracy and applicability of blood-based multi-cancer early detection (MCED) in the general population. J Clin Oncol, 2023;41(16_suppl):3069; doi: 10.1200/JCO.2023.41.16_suppl.3069
5.
NicholsonBD, OkeJ, VirdeePS, et al.Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): A large-scale, observational cohort study. Lancet Oncol, 2023;24:733–743; doi: 10.1016/S1470-2045(23)00277-2
